XNASHBIO
Market cap90mUSD
Dec 24, Last price
2.08USD
1D
-0.95%
1Q
-21.80%
Jan 2017
-31.80%
IPO
-52.29%
Name
Harvard Bioscience Inc
Chart & Performance
Profile
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
IPO date
Oct 21, 2013
Employees
436
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 112,250 -0.96% | 113,335 -4.68% | 118,904 16.46% | |||||||
Cost of revenue | 104,831 | 114,379 | 110,998 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 7,419 | (1,044) | 7,906 | |||||||
NOPBT Margin | 6.61% | 6.65% | ||||||||
Operating Taxes | 859 | 337 | 148 | |||||||
Tax Rate | 11.58% | 1.87% | ||||||||
NOPAT | 6,560 | (1,381) | 7,758 | |||||||
Net income | (3,415) -64.11% | (9,516) 3,204.17% | (288) -96.31% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (1,051) | (200) | ||||||||
BB yield | 0.92% | 0.07% | ||||||||
Debt | ||||||||||
Debt current | 8,691 | 3,811 | 3,235 | |||||||
Long-term debt | 41,708 | 50,430 | 53,725 | |||||||
Deferred revenue | (1,558) | |||||||||
Other long-term liabilities | 1,476 | 6,288 | 8,532 | |||||||
Net debt | 46,116 | 50,066 | 50,697 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 14,028 | 1,152 | 1,262 | |||||||
CAPEX | (1,788) | (1,590) | (1,345) | |||||||
Cash from investing activities | (1,799) | (1,590) | (1,345) | |||||||
Cash from financing activities | (12,134) | (2,837) | (252) | |||||||
FCF | 1,446 | 3,171 | 673 | |||||||
Balance | ||||||||||
Cash | 4,283 | 4,508 | 7,821 | |||||||
Long term investments | (333) | (1,558) | ||||||||
Excess cash | 318 | |||||||||
Stockholders' equity | (159,361) | (156,788) | (142,249) | |||||||
Invested Capital | 278,100 | 282,120 | 280,730 | |||||||
ROIC | 2.34% | 2.77% | ||||||||
ROCE | 6.21% | 5.65% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 42,420 | 41,413 | 40,343 | |||||||
Price | 5.35 93.14% | 2.77 -60.71% | 7.05 64.34% | |||||||
Market cap | 226,947 97.84% | 114,714 -59.67% | 284,418 71.58% | |||||||
EV | 273,063 | 164,780 | 335,115 | |||||||
EBITDA | 14,417 | 6,531 | 15,527 | |||||||
EV/EBITDA | 18.94 | 25.23 | 21.58 | |||||||
Interest | 3,591 | 2,246 | 1,540 | |||||||
Interest/NOPBT | 48.40% | 19.48% |